Evidence map›Paper›PMID 39085372›Full record

ArticleBone marrow transplantation2024

HLA evolutionary divergence (HED) informs the effect of HLA-B mismatch on outcomes after haploidentical transplantation.

Melhem Solh, Michael T Aubrey, Xu Zhang, Asad Bashey, Brian M Freed, Christina L Roark, Lizamarie Bachier-Rdriguez, Lawrence E Morris, H Kent Holland, Scott R Solomon

Abstract read
PubMed Publisher
In one paragraph

Article in Bone marrow transplantation, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Melhem SolhThe Blood and Marrow Transplant Program at Northside Hospital, Atlanta, GA, USA. msolh@bmtga.com.ORCID http://orcid.org/0000-0003-3766-5623
Michael T AubreyUniversity of Colorado Blood Bank and Clinimmune Laboratory, Aurora, CO, USA.
Xu ZhangSchool of Public Health, University of Texas, Houston, TX, USA.
Asad BasheyThe Blood and Marrow Transplant Program at Northside Hospital, Atlanta, GA, USA.
Brian M FreedUniversity of Colorado Blood Bank and Clinimmune Laboratory, Aurora, CO, USA.
Christina L RoarkUniversity of Colorado Blood Bank and Clinimmune Laboratory, Aurora, CO, USA.
Lizamarie Bachier-RdriguezThe Blood and Marrow Transplant Program at Northside Hospital, Atlanta, GA, USA.
Lawrence E MorrisThe Blood and Marrow Transplant Program at Northside Hospital, Atlanta, GA, USA.
H Kent HollandThe Blood and Marrow Transplant Program at Northside Hospital, Atlanta, GA, USA.
Scott R SolomonThe Blood and Marrow Transplant Program at Northside Hospital, Atlanta, GA, USA.ORCID http://orcid.org/0000-0003-2061-8126

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Graft versus tumor relies on tumor-associated antigens (TAAs) that are presented to donor T cells via human leukocyte antigens (HLAs). The HLA evolutionary divergence (HED) between alleles of a single individual can dictate the ability to present TAAs. The impact of HED in haploidentical donor transplantation (HIDT) has not been studied. We studied the effect of HED on transplant outcomes following HIDT. We analyzed 322 consecutive recipient/donor pairs with a median follow-up of 57.2 months. Pairwise divergence of HLA class I and II showed that HLA-B, -DRB1, and -DQB1 contributing most to mean HED. The mean HED was class I 6.85 (HLA-A 7.08, -B 8.24, and -C 5.07), class II 8.58 (HLA-DRB1 10.97, -DQB1 10.06 and -DPB1 4.06). A high HED in class I mismatched recipient/donor haplotype (RD MM) was significant for worse DFS (HR 1.11, p = 0.020), and relapse (HR 1.11, p = 0.02). Also, a high HED in RD MM HLA-B haplotype had worse OS (HR 1.07, p = 0.02), DFS (HR 1.09, p = 0.002), higher relapse (HR 1.10, p = 0.003), and similar NRM to low HED. The multivariate analysis showed that high HED in RD MM HLA-B (≥7.8 vs <7.8) had worse DFS (HR 1.53, p = 0.01), higher relapse (HR 1.61, p = 0.024), and similar NRM and OS.

Indexed as

Evolution, MolecularHLA-B AntigensTransplantation, HaploidenticalAdultAgedAged, 80 and overBiological EvolutionFemaleHLA AntigensHumansMaleMiddle AgedRetrospective StudiesTreatment OutcomeYoung AdultHLA AntigensHLA-B Antigens

Identifiers

PMID39085372

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.